Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Recruiting

Phase 3

TulisokibartExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06651281

Conditions

Crohn Disease

Colitis, Ulcerative

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Tulisokibart

Placebo to tulisokibart

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-06. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-10-27.